SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Provectus Pharmaceuticals Inc. -- Ignore unavailable to you. Want to Upgrade?


To: jm2i123 who wrote (11163)4/23/2012 2:41:42 PM
From: Mammon1 Recommendation  Read Replies (1) | Respond to of 13111
 
We don't have to give over the board to nattering negativism. I'd like to discuss subjects like

what are the pros and cons of doing the phase III trials with or without a partner
what a potential derm deal might look like
how provectus compares to other biotech companies that have recently been bought out
if there's any chance for accelerated approval given the Moffitt studies
how the psoriasis results compare to other gels [not systemic treatments]
how pv10 might work as a first defense drug.
the pharmaceutical companies perception of pvct
when does this company's stock price start to represent its true value?

I just read an interesting article in this week's New Yorker about the resurgence of immunology in cancer treatment. We're on the cusp of something groundbreaking here, imho.



To: jm2i123 who wrote (11163)4/23/2012 2:42:29 PM
From: Jack Russell  Read Replies (1) | Respond to of 13111
 
JM believe it or not I don't look at it like it is "my Board" ... It is everyone's board and I try to be as inclusive as possible but I still get people on one side saying I should be doing it a certain way and people on the other side saying do it another way... Damned if I do damned if I don't... I think I will just try to keep the peace as best I can from now on and ban those that post off topic to much...
This is (I hope) my last public post on the subject....